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Abstract
Introduction Inflammation within the tumour microenvironment
correlates with increased invasiveness and poor prognosis in
many types of cancer, including breast cancer. We have
previously demonstrated that activation of a mouse mammary
tumour virus (MMTV)-driven inducible fibroblast growth factor
receptor 1 (iFGFR1) transgene in mammary epithelial cells
results in an inflammatory response characterised by induction
of inflammatory genes in the mammary gland. Specifically, we
have observed increased levels of IL-1 expression in the
mammary gland following activation of iFGFR1 and have used
the iFGFR1 model to elucidate the function of IL-1 in
promoting iFGFR1-induced mammary lesions.
Methods To determine the functional consequences of IL-1
induction during FGFR1-induced mammary tumourigenesis, the
effects of IL-1 inhibition on the formation of epithelial
hyperplasias were examined using the MMTV-iFGFR1
transgenic mouse model. Further studies used a combination of
the HC-11 mammary epithelial cell line that stably expresses
iFGFR1 and the MMTV-iFGFR1 transgenic mice to further
define the mechanisms of IL-1 function.
Results Inhibition of IL-1 activity in vivo resulted in reduced
iFGFR1-induced epithelial proliferation and formation of
hyperplastic structures. Further studies demonstrated that
treatment of mammary epithelial cells with IL-1-induced
expression of cyclooxygenase (Cox)-2 both in vitro and in vivo.
Finally, inhibition of Cox-2 prior to activation of iFGFR1 in the
transgenic mice also resulted in decreased iFGFR1-induced
formation of hyperplastic structures.
Conclusions The results from these studies indicate that
targeting the inflammatory cytokine IL-1 partially inhibits
iFGFR1-induced formation of early-stage mammary lesions, in
part through induction of Cox-2. These findings demonstrate
that activation of a growth factor receptor in mammary epithelial
cells results in increased expression of inflammatory mediators,
which cooperate to promote the initiation of hyperplastic lesions
in the mammary gland.
Introduction
Inflammation is a well-known risk factor for tumour develop-
ment and correlates with increased invasiveness and poor
prognosis in a variety of cancers [1]. It is well-established that
chronic inflammation that is driven by extrinsic factors pro-
motes several types of cancer, including gastric, hepatic and
gastrointestinal cancers [1]. However, inflammation has also
been correlated with the development of cancers that are not
typically associated with chronic inflammatory states, such as
breast cancer. There has been ongoing interest in the concept
that intrinsic factors, such as activation of an oncogene within
epithelial cells, induce a state of localised inflammation that
subsequently promotes tumourigenesis [2].
Recent epidemiological studies support a role for anti-inflam-
matory drugs in the reduction of breast cancer risk [3-7].
Cox-2: cyclooxygenase 2; ELISA: enzyme linked immunosorbent assay; FGFR1: fibroblast growth factor receptor 1; GAPDH: glyceraldehyde 3-phos-
phate dehydrogenase; H&E: haematoxylin and eosin; iFGFR1: inducible fibroblast growth factor receptor 1; Ig: immunoglobulin; IL: interleukin; IL-1R: 
interleukin-1 receptor; i.p.: intraperitoneally; MMTV: mouse mammary tumour virus; NF: nuclear factor; NSAID: non-steroidal anti-inflammatory drug; 
pH3: phospho-histone H3; rm: recombinant murine; RT-PCR: reverse transcription polymerase chain reaction.Breast Cancer Research    Vol 11 No 2    Reed et al.
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Furthermore, inflammatory cytokines, such as IL-1, and other
mediators of inflammation have been linked to breast cancer
formation and recurrence [8,9]. Cyclooxygenase (Cox)-2 is a
primary downstream target of inflammatory cytokines and has
been linked to proliferation, suppression of apoptosis, induc-
tion of genomic instability, resistance to treatment and angio-
genesis in breast cancer [10,11]. Although Cox-2 is commonly
associated with inflammatory cells, studies have also demon-
strated that Cox-2 is induced by activation of oncogenes
within breast cancer cells [12,13]. Therefore, Cox-2 is likely to
represent an important component of intrinsically induced
inflammation in breast cancer. Understanding the mechanisms
by which intrinsic factors, such as oncogenes, induce inflam-
mation is critical for successfully developing and using anti-
inflammatory strategies to target breast cancer formation and
recurrence.
Using an inducible mouse model of mammary tumourigenesis,
we previously demonstrated that activation of an inducible
fibroblast growth factor receptor-1 (iFGFR1) transgene within
epithelial cells resulted in the formation of hyperplastic bud-
ding structures within 48 hours of iFGFR1 activation [14,15].
These early structures were characterised by increased prolif-
eration and lack of formation of a proper lumen surrounded by
the epithelium [15]. Longer-term activation demonstrated that
iFGFR1 activation promoted a loss of myoepithelial cells, and
increased angiogenesis, formation of locally invasive lesions
and, ultimately, mammary tumour formation [14,15]. Further
studies of this model demonstrated that iFGFR1 activation in
the mammary gland induced a rapid, localised inflammatory
response, characterised by recruitment of macrophages to the
epithelial structures and induction of inflammatory genes by
microarray analysis [14]. Activation of iFGFR1 has been
shown to promote proliferation, survival, migration, invasion
and epithelial-mesenchymal transition of mammary epithelial
cells [16]. Furthermore, FGFR1 is amplified in 10% of human
breast tumours and has been linked to a poor response to
treatment in breast cancer patients [17]. However, the mech-
anisms by which FGFR1 activation in epithelial cells induces
pro-tumourigenic effects in the microenvironment are only
beginning to be understood.
Our current studies focus on the ability of iFGFR1 activation
to promote an intrinsic pathway of inflammation using a trans-
genic mouse model. We have found that activation of iFGFR1
within mammary epithelial cells results in the expression of
proinflammatory genes, such as IL-1 and Cox-2, and that
these mediators are important for iFGFR1-induced early-stage
tumourigenesis. These studies demonstrate that activation of
an oncogenic growth factor signalling pathway within mam-
mary epithelial cells induces a localised inflammatory response
that promotes the formation of early-stage mammary lesions.
Materials and methods
Animals
Generation of mouse mammary tumour virus (MMTV)-iFGFR1
transgenic mice has been described previously [15] and the
mice were obtained from Dr Jeff Rosen (Baylor College of
Medicine, Houston, TX, USA). Animal care and procedures
were approved by the Institutional Animal Care and Use Com-
mittee of the University of Minnesota and were in accordance
with the procedures detailed in the Guide for Care and Use of
Laboratory Animals.
Treatment of mice
For iFGFR1 activation, six-week-old female mice were injected
intraperitoneally (i.p.) with 1 mg/kg AP20187 (Ariad Pharma-
ceuticals, Cambridge, MA, USA) twice weekly. Mice were sac-
rificed at 48 hours and four weeks post-injection and
mammary glands from at least three mice were analysed per
time point. For the IL-1 neutralisation studies, the mice were
treated as described previously [18]. Briefly, mice were
injected i.p. with 4 g/g IL-1 antibody (AB-401-NA, R&D Sys-
tems, Minneapolis, MN, USA) 24 hours prior to AP20187
treatment and in conjunction with AP20187 for an additional
48 hours. Control mice were injected with isotype control total
immunoglobulin (Ig) G (R&D Systems, Minneapolis, MN, USA)
for the same time frame. For inhibition of Cox-2 by celecoxib,
four-week-old female MMTV-iFGFR1 transgenic mice and
non-transgenic littermate control mice were fed standard
mouse chow (Harlan Laboratories, Madison, WI, USA)
enriched with celecoxib (obtained as 200 mg capsules) at a
concentration of 1000 mg/kg (Harlan Laboratories, Madison,
WI, USA). Celecoxib-treated mice and control mice, given
standard mouse chow only, were fed for one week. All mice
were then injected i.p. with 1 mg/kg AP20187. Mice were
maintained on the celecoxib or control diets and were sacri-
ficed 48 hours post-injection. Mammary glands from five mice
per treatment group were removed for whole mount and histo-
logical analysis.
Mammary gland whole mounts, histology and 
measurement of epithelial budding
Whole mounts were prepared as described previously [14].
For embedding, sectioning and immunohistochemistry, mam-
mary glands were fixed for two hours in 4% paraformaldehyde
and embedded in paraffin. For histological analysis, the glands
were sectioned and stained with H&E using standard histolog-
ical protocols. To quantify epithelial budding structures, six
images were taken per mammary gland section at 10× magni-
fication. Five sections were analysed per gland, each approxi-
mately 100 m apart, to compensate for variability within the
gland. In addition, only epithelial structures distal to the lymph
node were included in the analyses due to the predominant
localisation of the hyperplastic phenotype along ducts leading
to terminal end buds. The total number of epithelial structures
was counted and expressed as a percentage of structures that
contain epithelial buds. At least three mice and 200 epithelialAvailable online http://breast-cancer-research.com/content/11/2/R21
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structures were analysed for each genotype and treatment. All
statistical analyses were performed using the unpaired stu-
dent's t-test to compare two means (GraphPad Prism, La Jolla,
CA, USA).
Immunohistochemistry
The following antibodies and dilutions were used for immuno-
histochemistry: rabbit polyclonal IL-1 (sc-7884), 1:100, goat
polyclonal Cox-2 (sc-1747), 1:100, (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), mouse monoclonal phospho-his-
tone H3 (pH3; 05-806, Millipore, Billerica, MA, USA).
Immunostaining was performed either with (IL-1, pH3) or
without (Cox-2) sodium citrate antigen retrieval, as described
previously [19]. pH3 and Cox-2 positive cells were counted
and calculated relative to the number of total epithelial cells. At
least 2000 cells from a total of three mice per treatment group
were counted for each dataset. All statistical analyses were
performed using the unpaired student's t-test to compare two
means.
RNA isolation and quantitative RT-PCR analysis
Transgenic and non-transgenic six-week mice were treated for
8, 16, 24 and 48 hours with AP20187, IgG isotype control
and/or IL-1 blocking antibody as indicated. Mammary glands
were isolated, the lymph nodes were removed and the mam-
mary glands were ground under liquid nitrogen and lysed in 2
mls of Trizol (Invitrogen, Carlsbad, CA, USA). RNA was
extracted from monolayer cells using Trizol as recommended
by the manufacturer. cDNA was generated using the Quanti-
tect Reverse Transcription kit (Qiagen, Valencia, CA, USA).
One-tenth of the final reaction volume was used in quantitative
SYBR (Synergy Brands) green RT-PCR reactions as
described previously [20] using the Bio-Rad iQ5 system (Bio-
Rad, Hercules, CA, USA). Relative quantification of the
expression of each gene was calculated and normalised to
averaged cyclophilin and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) expression levels as indicated using the
2-Ct method [21]. The following primer sequences were
used: IL-1 5'-GCAACTGTTCCTGAACTCAAC-3' and 5'-
ATCTTTTGGGGTCCGTCAACT-3', Cox-2 5' TGAGCAAC-
TATTCCAAACCAG-3' and GCACGTAGTCTTCGATCAC-
TATC, cyclophilin 5'-TGAGCACTGGGGAGAAAGG-3' and
5'TTGCCATCCAGCCACTCAG-3', GAPDH 5'-TGAC-
CACAGTCCATGCCATC-3' and 5'-GACGGACACATT-
GGGGGTAG-3'. All statistical analyses were performed
using the unpaired student's t-test to compare two means.
Cell culture and immunoblot analysis
Generation of HC-11 cells stably expressing the iFGFR1 con-
struct was described previously [16] and the cells were
obtained from Dr Jeff Rosen (Baylor College of Medicine, Hou-
ston, TX, USA). The cells were incubated in serum-free RPMI
media for 16 hours prior to treatment with either the indicated
amounts of recombinant IL-1 (Pierce Endogen, Rockford, IL,
USA) or with 30 nM AP20187 for the indicated times. The
cells were lysed in radio immuno precipitation assay buffer and
protein-containing supernatants were generated by centrifu-
gation. Equal amounts of protein were analyaed by SDS-
PAGE and immunoblotting analysis was performed with the
following antibodies at a dilution of 1:1000: phospho-p65
(3033), p65 (4764), Cox-2 (4842) and -tubulin (2146) (Cell
Signaling Technology, Beverly, MA, USA). Densitometry was
performed using an AlphaImager 3400 (Alpha Innotech, San
Leandro, CA, USA).
Co-culture and ELISA analysis
RAW 264.7 cells (American Type Culture Collection, Manas-
sas, VA, USA) and HC-11/R1 cells were plated at equal den-
sities in six-well tissue culture plates and allowed to grow for
48 hours in complete HC-11/R1 media. The cells were incu-
bated overnight in serum-free RPMI media and treated with
either 30 nM AP20187 or an equal amount of ethanol as a sol-
vent control. Following eight hours of treatment, the cells were
harvested in Trizol and IL-1 expression levels were analysed
as described above. Following 24 hours, conditioned medium
was harvested and was analysed using an ELISA to quantify
the amount of IL-1 in the media following the manufacturer's
protocols (R&D Systems, Minneapolis, MN, USA). All statisti-
cal analyses were performed using the unpaired students t-
test to compare two means.
Migration assays
Migration assays were performed as described previously
[16]. Briefly, HC-11/R1 cells were grown to confluence and
incubated overnight in serum-free medium. A p20 pipet tip
was used to make a scratch down the centre of the well and
pictures were taken of the scratch prior to treatment of cells
with 30 nM AP20187 and/or 5 ng/ml recombinant IL-1. After
18 hours, pictures were taken again and the area of the gap
closure was quantified using Leica LAS software (Leica Micro-
systems, Wetzlar, Germany). All statistical analyses were per-
formed using the unpaired student's t-test to compare two
means.
Results
Activation of iFGFR1 in mammary epithelial cells 
induces expression of the inflammatory cytokine IL-1 in 
the mammary gland
FGFR1 is amplified in approximately 8 to 10% of human
breast cancers [22]. However, due to lack of a ligand that spe-
cifically activates FGFR1 without activating the other FGFRs,
a model was developed to study the effects of FGFR1 activa-
tion specifically in mammary epithelial cells [15]. In this model,
a modified, membrane-targeted FGFR1 (iFGFR1) that lacks
an extracellular domain is activated by treatment of cells with
a lipid-soluble dimeriser, AP20187. Upon binding, AP20187
induces homodimerisation and activation of the receptor. The
effects of activating this FGFR1 construct in mammary epithe-
lial cells in cell culture and in vivo using the MMTV-iFGFR1
transgenic mouse model have been described previously [14-Breast Cancer Research    Vol 11 No 2    Reed et al.
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16,23]. Specifically, iFGFR1 activation in the mammary gland
results in the rapid formation of hyperplastic epithelial struc-
tures within 48 hours accompanied by an inflammatory
response, characterised by rapid macrophage recruitment and
increased expression of several inflammatory genes [14,15].
To identify inflammatory genes that contribute to the iFGFR1-
induced inflammatory response, we used quantitative RT-PCR
analysis to examine the expression of several candidate genes
in the mammary gland following treatment of mice with
AP20187, which activates iFGFR1. Interestingly, we found a
significant induction of IL-1, which is a critical cytokine in the
inflammatory response that has also been linked to breast can-
cer invasiveness and recurrence [8,9]. As shown in Figure 1a,
expression of IL-1 mRNA increased significantly in the mam-
mary gland within eight hours and remained elevated following
24 hours of iFGFR1 activation. Treatment of non-transgenic lit-
termates with AP20187 did not induce a similar increase in IL-
1 expression, demonstrating that this response was not a
general inflammatory reaction to either the AP20187 dimeriser
or the solvent used for the injections (Figure 1a). In addition to
gene expression levels, immunohistochemical analysis of
mammary gland sections demonstrated an increase in IL-1
protein expression following 48 hours of iFGFR1 activation in
comparison to non-transgenic littermates treated with
AP20187 (Figures 1b,c). Analysis of a four-week time-point
revealed sustained expression of IL-1 associated with
iFGFR1-induced hyperplastic lesions (Figures 1d,e). These
results demonstrate that activation of iFGFR1 in mammary epi-
thelial cells results in expression of the key inflammatory medi-
ator, IL-1, in the mammary gland.
Because IL-1 is secreted, the cellular source of the IL-1 in
the mammary gland is difficult to discern using immunohisto-
chemistry. Therefore, we utilised in vitro assays to determine
whether iFGFR1 directly induces expression of IL-1 in mam-
mary epithelial cells. For these studies, we used a derivative of
the HC-11 cell line, which is a mouse mammary epithelial cell
line derived from a mid-pregnant Balb/c mammary gland [24].
To study the consequences of iFGFR1 activation in these
cells, clones of HC-11 cells were previously generated that
stably express iFGFR1 (HC-11/R1) [16]. Published studies
have demonstrated that activation of iFGFR1 in these cells
promotes proliferation, survival, migration and invasion
[16,23]. Therefore, these cells represent a relevant in vitro
model with which to examine iFGFR1-mediated mechanisms
of mammary tumourigenesis.
To determine the effects of iFGFR1 activation on IL-1 expres-
sion, the cells were treated with 30 nM AP20187 and IL-1
expression was analysed using both quantitative RT-PCR and
ELISA assays. Although we detected a small increase in IL-1
mRNA expression (Figure 1f), this induction was not statisti-
cally significant. Furthermore, no IL-1 protein was detected in
conditioned media using an ELISA assay (data not shown).
Therefore, we hypothesised that activation of iFGFR1-induced
expression of IL-1 requires the presence of other cell types.
We had previously observed a rapid accumulation of macro-
phages around the hyperplastic epithelial structures following
iFGFR1 activation in the mammary gland [14]. Furthermore,
macrophages are known to secrete high levels of IL-1 in
response to inflammatory stimuli [25]. Therefore, we analysed
IL-1 expression levels following activation of iFGFR1 in epi-
thelial cell/macrophage co-cultures. Interestingly, significant
increases in both IL-1 mRNA and protein were detected in
the co-cultures (Figures 1f,g). Similar results were found when
the HC-11/R1 cells were co-cultured with mouse bone mar-
row-derived macrophages (data not shown). These results
suggest that interactions between epithelial cells and macro-
phages may be required to induce IL-1 following iFGFR1
activation in the mammary epithelial cells in vitro.
IL-1 promotes the formation of iFGFR1-induced 
hyperplasias in vivo
Based on the increased expression of IL-1 following FGFR1
activation and the link between IL-1 and breast cancer [8],
we hypothesised that IL-1 may be an important factor in the
formation of iFGFR1-induced proliferative lesions. To examine
this hypothesis, we used a systemic IL-1 neutralisation strat-
egy similar to that described previously [18]. For these exper-
iments, either an IL-1 neutralising antibody or an equivalent
amount of an isotype control goat IgG antibody was adminis-
tered i.p. to six-week-old female transgenic mice 24 hours
prior to iFGFR1 activation. The mice were then treated with
AP20187 to activate iFGFR1 in conjunction with daily treat-
ments of either IL-1 blocking antibody or an isotype control
goat IgG for 48 hours. Following the treatments, the mammary
glands were analysed by whole mount analysis and sections
were analysed for the percentage of budding epithelial struc-
tures, proliferation and macrophage recruitment. Analysis of
whole mounts revealed that IL-1 inhibition led to an overall
decrease in hyperplastic budding, particularly associated with
the terminal-end buds and the subtending ducts (see Addi-
tional data file 1). Further studies were performed to validate
these alterations in histological sections. We found that
although inhibition of IL-1 did not completely abolish hyper-
plastic budding of the epithelium, there was a significant
decrease in the total number of budding structures present
within mammary glands from mice that had been treated with
the IL-1 blocking antibody (Figures 2a to 2d). Furthermore,
there was a corresponding decrease in the percentage of pro-
liferating epithelial cells as measured by quantification of pH3
immunofluorescence (Figure 2e). Interestingly, analysis of
macrophage recruitment revealed that inhibition of IL-1 activ-
ity did not affect iFGFR1-induced recruitment of macrophages
to the epithelium (data not shown). Together, these studies
suggest that although IL-1 may not be critical for the recruit-
ment of macrophages observed in this model, IL-1 activity
contributes to epithelial proliferation during the formation of
the iFGFR1-induced lateral budding phenotype.Available online http://breast-cancer-research.com/content/11/2/R21
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Figure 1
iFGFR1 activation induces IL-1 expression in the mammary gland iFGFR1 activation induces IL-1 expression in the mammary gland. (a) Mouse mammary tumour virus (MMTV) inducible fibroblast growth factor 
receptor 1 (iFGFR1) transgenic mice and non-transgenic littermate controls were treated with AP20187 for 8 and/or 24 hours. Non-treated mice 
were used as the baseline control. Quantitative RT-PCR was performed on RNA extracted from whole mammary gland tissue and normalised to 
expression levels of cyclophilin. Mammary glands from three separate mice were analysed per time point. Error bars represent standard error of the 
mean. ** P < 0.01, *** P < 0.001. (b to e) Immunohistochemical analysis of mammary gland tissue sections from MMTV-iFGFR1 transgenic mice 
and non-transgenic littermate controls following either 48 hours or 4 weeks of AP20187 treatment. Images are representative of results from the 
analysis of three mice per genotype and treatment time. (f) Quantitative RT-PCR analysis of IL-1 expression levels (normalised to glyceraldehyde 3-
phosphate dehydrogenase). Either HC-11/R1 cells or HC-11/R1-RAW264.7 co-cultures were treated with AP20187 (+AP) or solvent (-AP) for four 
hours and analysed for IL-1 gene expression. * P < 0.05. (g) HC-11/R1-RAW264.7 co-cultures were treated with AP20187 (+AP) or solvent (-AP) 
for 18 hours and conditioned media was analysed using an ELISA. * P < 0.05.Breast Cancer Research    Vol 11 No 2    Reed et al.
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IL-1 induces activation of NFB in HC-11/R1 mammary 
epithelial cells
Based on the results from the in vivo studies, we hypothesised
that IL-1 acts on the mammary epithelial cells to contribute to
the formation of iFGFR1-induced hyperplastic lesions. There-
fore, initial studies were performed to ascertain the ability of
mammary epithelial cells to respond to IL-1 stimulation by
examining activation of downstream signalling pathways using
the HC-11/R1 cell line described previously. Initial studies
using both quantitative RT-PCR and immunoblot analysis
demonstrated that the HC-11/R1 cells express the IL-1 recep-
tor (IL-1R) (data not shown). Further studies were performed
using both dose-response and time-course analyses to exam-
ine the activation of nuclear factor (NF) B, which is a key
downstream target of IL-1 in other cell types [26]. Treatment
of HC-11/R1 cells with recombinant murine (rm) IL-1
resulted in a rapid induction of phosphorylation of the p65
subunit of NFB within 15 minutes of treatment as shown by
immunoblot analysis (Figures 3a,b). Based on the observation
that 5 ng/ml of rmIL-1 was within the linear range of response
(Figure 3a), this concentration was used for the remainder of
the studies. These results demonstrate that the HC-11/R1
mammary epithelial cell line responds to rmIL-1 treatment by
activating a well-defined downstream signalling pathway.
IL-1 and iFGFR1 cooperate to promote migration of HC-
11/R1 cells
Previous studies have demonstrated that treatment of breast
cancer cells in culture with IL-1 promotes cell proliferation
and migration [27,28]. Therefore, we examined the ability of IL-
1 to promote these properties in non-transformed mammary
epithelial cells using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide and scratch wounding assays, respec-
tively. In contrast to studies of breast cancer cells, treatment of
HC-11/R1 cells with rmIL-1 alone did not promote either pro-
liferation (data not shown) or migration (Figures 3c,d).
Because IL-1 can promote these properties in breast cancer
cells, we hypothesised that IL-1 may act cooperatively with
another oncogenic stimulus to promote tumourigenic
changes. Therefore, we stimulated HC-11/R1 cells with
Figure 2
Analysis of mammary glands from iFGFR1 transgenic mice following activation of iFGFR1 and treatment with an IL-1 neutralising antibody Analysis of mammary glands from iFGFR1 transgenic mice following activation of iFGFR1 and treatment with an IL-1 neutralising antibody. H&E-
stained sections from (a) non-treated control mice, (b) transgenic mice treated with AP20187 and goat IgG, and (c) transgenic mice treated with 
AP20187 and IL-1 blocking antibody (Ab). Arrows indicate epithelial budding structures. Scale bar = 100 M. (d) Budding structures were quan-
tified by counting epithelial structures in H&E-stained sections (three mice per treatment group). Decreased epithelial budding was observed follow-
ing treatment with AP20187 and the IL-1 antibody compared with treatment with AP20187 and IgG. ** P < 0.01 (e) Sections were immunostained 
with an antibody to phospho-histone H3 (pH3), a marker of mitosis, and the percentage of pH3 positive epithelial cells was determined. Decreased 
numbers of pH3 were observed following treatment with AP20187 and the IL-1 antibody compared with treatment with AP20187 and IgG. * P < 
0.05, ** P < 0.01. iFGFR1 = inducible fibroblast growth factor receptor 1.Available online http://breast-cancer-research.com/content/11/2/R21
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AP20187, which activates iFGFR1, and rmIL-1 either alone
or in combination. Addition of IL-1 to the media did not signif-
icantly affect iFGFR1-induced proliferation of the HC-11/R1
cells (data not shown). However, addition of both AP20187
and rmIL-1 to the media promoted a significant increase in
migration in comparison with iFGFR1 activation alone (Figures
3c,d). These studies suggest that although treatment of non-
transformed mammary epithelial cells with IL-1 alone does
not promote the acquisition of tumourigenic properties, IL-1
may act cooperatively with other oncogenic stimuli to promote
these properties during tumour formation.
IL-1 and iFGFR1 induce expression of Cox-2, which 
promotes migration of HC-11/R1 cells in vitro
To identify downstream targets of IL-1 in mammary epithelial
cells, we asked whether IL-1 could induce expression of Cox-
2, a known IL-1 target [26], in the HC-11/R1 cells. For these
studies, HC-11/R1 cells were treated with rmIL-1 and Cox-2
expression was evaluated by quantitative RT-PCR and immu-
noblot analysis. Quantitative RT-PCR analysis demonstrated a
modest induction of both Cox-2 mRNA and protein following
four and six hours of IL-1 treatment, respectively (Figures
4a,c). Because Cox-2 is a known downstream target of growth
factor signalling pathways [12,13], we explored the possibility
that activation of iFGFR1 also induces Cox-2 expression. HC-
11/R1 cells were treated with AP20187 to activate iFGFR1
and Cox-2 expression was analysed by both quantitative RT-
PCR and immunoblot analysis. As shown in Figure 4b, Cox-2
mRNA and protein expression were rapidly induced in the HC-
11/R1 cells following iFGFR activation. Because Cox-2 is
induced by both iFGFR1 and IL-1 in the HC-11/R1 mammary
epithelial cells, we predicted that activation of both growth fac-
tor and cytokine-induced signalling pathways would result in a
cooperative induction of Cox-2 expression. In agreement with
this prediction, quantitative RT-PCR analysis revealed an addi-
tive increase in Cox-2 expression following activation of both
iFGFR1 and IL-1 signalling pathways in comparison with
either stimulation alone (Figure 4d). These results suggest that
Figure 3
IL-1 induces NFB activation and cooperates with iFGFR1 to promote migration in HC-11/R1 cells IL-1 induces NFB activation and cooperates with iFGFR1 to promote migration in HC-11/R1 cells. (a) HC-11/R1 cells were incubated in serum-
free medium overnight and then stimulated with the following concentration of recombinant IL-1 for 15 minutes: 50, 5, 0.5 and 0.05 ng/ml IL-1. 
Immunoblot analysis was performed to detect levels of phospho-p65 (upper panel) and total p65 (lower panel) as a loading control. (b) HC-11/R1 
cells were treated with 5 ng/ml recombinant murine (rm) IL-1 for the indicated times and immunoblot analysis was performed as described in a. (c, 
d) At confluency, HC-11/R1 cells were serum starved for 24 hours, scratched using a pipet tip and allowed to recover for 18 hours in the presence 
of IL-1, AP20187 or both. Pictures were taken immediately after the scratch and 18 hours later and were used to determine the extent of migration 
(d) measuring the changes in area between the scratch surfaces. Error bars represent standard error of the mean. ** P < 0.01, *** P < 0.001. 
iFGFR1 = inducible fibroblast growth factor receptor 1; NF = nuclear factor.Breast Cancer Research    Vol 11 No 2    Reed et al.
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signalling pathways induced by growth factors and cytokines
cooperate to promote increased levels of expression of inflam-
matory mediators. To determine whether iFGFR1-induced
expression of Cox-2 is dependent on IL-1, an IL-1 blocking
antibody was added to the media at the time of AP20187 stim-
ulation and Cox-2 expression was analysed by immunoblot
analysis. We found that inhibition of IL-1 activity did not sig-
nificantly affect Cox-2 expression levels (data not shown), sug-
gesting that iFGFR1 induces Cox-2 expression in an IL-1-
independent manner and it is likely that IL-1 and iFGFR1 act
Figure 4
IL-1 and iFGFR1 induce expression of Cox-2 in HC-11/R1 cells IL-1 and iFGFR1 induce expression of Cox-2 in HC-11/R1 cells. (a) HC-11/R1 cells were treated with 5 ng/ml rmIL-1 for the indicated times. 
Quantitative RT-PCR was used to analyse IL-1 mRNA expression (normalised to levels of cyclophilin and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH)). Error bars represent standard error of the mean. ** P < 0.01. (b) HC-11/R1 cells were treated with either 30 nM AP20187 or eth-
anol (Sol) for the indicated times and cyclooxygenase (Cox) 2 mRNA expression was analysed and normalised as described in a. * P < 0.05, ** P < 
0.01. (c) HC-11/R1 cells were stimulated with either 5 ng/ml recombinant murine (rm) IL-1 or 30 nM AP20187 for the indicated times. Immunoblot 
analysis was performed using antibodies specific for Cox-2 and -tubulin as a loading control. Densitometry was performed to analyse Cox-2 expres-
sion levels relative to -tubulin. (d) HC-11/R1 cells were treated with 30 nM AP20187 and 5 ng/ml rmIL-1 for one hour. Quantitative RT-PCR anal-
ysis was performed to examine levels of Cox-2 expression, which were normalised to levels of cyclophilin and GAPDH. Error bars represent standard 
error of the mean. ** P < 0.01, *** P < 0.001. (e) Migration assays were performed as described in Figure 3. Cells were treated with 30 nM 
AP20187 and/or 5 ng/ml IL-1 in the presence of either celecoxib or dimethyl sulfoxide (DMSO) as a solvent control as indicated. Error bars repre-
sent standard error of the mean. * P < 0.05, ** P < 0.01. iFGFR1 = inducible fibroblast growth factor receptor 1.Available online http://breast-cancer-research.com/content/11/2/R21
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through different signalling pathways to induce Cox-2
expression.
Because Cox-2 has been implicated in promoting breast can-
cer cell motility [29], we hypothesised that induction of Cox-2
was required for the synergistic effect of iFGFR1 and IL-1 on
migration. To examine this hypothesis, HC-11/R1 cells were
treated with the Cox-2 selective inhibitor, celecoxib. As shown
in Figure 4e, addition of 25 M celecoxib to the media resulted
in a significant inhibition of migration induced by iFGFR1 acti-
vation. Furthermore, celecoxib also inhibited the migration
induced by both iFGFR1 and IL-1 (Figure 4e), suggesting
that Cox-2 is a critical mediator of migration induced by
iFGFR1 activation and by iFGFR1/IL-1 co-stimulation.
iFGFR1 activation in mammary epithelial cells induces 
expression of Cox-2 in vivo
To explore the mechanisms by which IL-1 promotes the
iFGFR1-induced mammary phenotype in vivo, we examined
expression levels of Cox-2 following iFGFR1 activation using
immunohistochemistry. As shown in Figure 5, increased
expression of Cox-2 was observed in the mammary gland
within 48 hours of iFGFR1 treatment (Figures 5a,c). Analysis
of mammary glands following four weeks of treatment demon-
strated sustained increased levels of Cox-2 associated with
hyperplastic lesions (Figures 5a, c). To correlate the expres-
sion of Cox-2 with IL-1 activity, we examined Cox-2 expres-
sion in mammary gland sections from the mice treated with the
IL-1 neutralising antibody. In comparison with mammary
glands from mice treated with the IgG isotype control anti-
body, inhibition of IL-1 activity resulted in decreased Cox-2
expression in epithelial structures following 48 hours of treat-
ment (Figures 5b, c). Interestingly, Cox-2 expression was not
completely abolished and remained detectable in some cells
(Figure 5c, arrow). Furthermore, analysis of Cox-2 mRNA
expression analysed in the mammary glands by quantitative
RT-PCR analysis demonstrated a decrease in Cox-2 gene
expression in mammary glands from the mice treated with the
IL-1 blocking antibody (Figure 5d). Consistent with the immu-
nohistochemistry studies, Cox-2 gene expression was only
partially reduced (Figure 5d). These results suggest that acti-
vation of iFGFR1 in mammary epithelial cells in vivo results in
induction of Cox-2, which is mediated in part by IL-1 activity.
However, inhibition of IL-1 activity did not completely abolish
Cox-2 expression, suggesting that iFGFR1 may induce Cox-2
expression via alternate pathways as suggested by the in vitro
studies.
Cox-2 promotes the formation of iFGFR1-induced 
mammary lesions
Although studies have demonstrated that Cox-2 promotes
late-stage mammary tumourigenesis [30], the role of Cox-2 in
the initial formation of early proliferative mammary lesions is
unknown. Therefore, to examine the role of Cox-2 in this model,
mice were provided with standard mouse chow supplemented
with celecoxib for one-week prior to treatment with AP20187
to activate iFGFR1. Mice were then injected i.p. with
AP20187 for 48 hours before mammary glands were removed
for further analysis. Tissue samples were then stained with
H&E for quantification of budding epithelial structures. As
expected, mammary glands from mice treated with AP20187
in the absence of celecoxib exhibited increased extensive bud-
ding epithelial structures in comparison to mammary glands
from non-transgenic mice treated with AP20187 (Figures 6a
to 6d). Although celecoxib treatment did not completely erad-
icate the hyperplastic budding structures, there was a signifi-
cant decrease in the percentage of extensive budding
structures in mammary glands from mice given celecoxib-
enhanced chow following AP20187 treatment (Figure 6d).
Furthermore, the number of epithelial structures with no dis-
cernible budding was increased on treatment with celecoxib
(Figure 6d), suggesting a delay in the formation of the iFGFR1-
induced lateral budding phenotype. Notably, Cox-2 inhibition
did not appear to inhibit formation of the hyperplastic lesions
as well as IL-1 inhibition, as determined by observing whole
mounts following celecoxib treatment (data not shown). This
suggests that either IL-1 blocking antibodies are more effi-
cient than celecoxib or that IL-1 can act through other down-
stream targets in the mammary gland. Overall, these data
demonstrate that IL-1 and Cox-2 are involved in the formation
of the iFGFR-induced hyperplastic phenotype and that target-
ing inflammatory mediators during early stages of mammary
tumourigenesis may result in decreased formation of prolifera-
tive lesions.
Discussion
Inflammation has been linked to the development of many
types of cancer, including breast cancer [1,31]. Epidemiolog-
ical studies have suggested that the use of non-steroidal anti-
inflammatory drugs (NSAIDs) can decrease the relative risk of
developing breast cancer [3-7,32,33]. These studies have led
to the recent exploration of the use of Cox-2 inhibitors to treat
breast cancer patients [32,34]. However, the origins of inflam-
mation in breast cancer are still not well understood. Unlike
other cancers in which chronic inflammation is associated with
extrinsic factors such as bacterial or viral infection, breast can-
cer has not been linked to extrinsically induced inflammatory
stimuli. Therefore, understanding the mechanisms by which
inflammation might be induced in the breast will lead to impor-
tant insights into developing anti-inflammatory strategies that
may prevent the development and recurrence of invasive
breast cancer.
We previously demonstrated that activation of iFGFR1 in
mammary epithelial cells in vivo induced a rapid inflammatory
response characterised by induction of inflammatory genes
and recruitment of macrophages [14]. We have further used
this model to explore the role of inflammation in promoting the
formation of iFGFR1-induced hyperplastic lesions. For the cur-
rent studies, we have focused on IL-1, which is a potentBreast Cancer Research    Vol 11 No 2    Reed et al.
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Figure 5
Activation of iFGFR1 induces Cox-2 expression in vivo, which is regulated in part by IL-1 activity Activation of iFGFR1 induces Cox-2 expression in vivo, which is regulated in part by IL-1 activity. (a) Cyclooxygenase (Cox) 2 immunohistochemis-
try of mammary gland sections from either non-transgenic or transgenic mice treated with AP20187 for either 48 hours or 4 weeks. (b) Cox-2 immu-
nohistochemistry of mammary gland sections from transgenic mice treated with either an isotype goat IgG or a neutralising IL-1 antibody in 
conjunction with AP20187 treatment. Magnification is 50 M. The figure is representative of sections from three mice per treatment. (c) Percentage 
of epithelial cells expressing Cox-2 in panels a and b. Error bars represent standard error of the mean. * P < 0.05, ** P < 0.01. (d) Quantitative RT-
PCR was used to analyse Cox-2 expression in mammary glands from non-transgenic and transgenic mice following treatment with AP20187 and 
either IgG or IL-1 blocking antibody. Cox-2 expression was normalised to cyclophilin expression. Error bars represent standard error of the mean. * 
P < 0.05, ** P < 0.01. Ab = antibody; IHC = immunohistochemistry; MMTV = mouse mammary tumour virus; NF = nuclear factor; iFGFR1 = induc-
ible fibroblast growth factor receptor 1.Available online http://breast-cancer-research.com/content/11/2/R21
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proinflammatory cytokine that has been linked to breast cancer
invasiveness and recurrence [8,35]. Studies of IL-1 in breast
cancer have demonstrated that IL-1 expression is increased
in 90% of oestrogen receptor-negative invasive breast carci-
nomas, and that it is localised to both tumour cells and stromal
cells [9,36]. In vitro studies of breast cancer cells have dem-
onstrated the ability of IL-1 to promote proliferation and
migration [27,28]. However, the mechanisms by which IL-1
acts on tumour cells and/or cells within the stroma to promote
breast cancer in vivo are not well understood.
Because our results clearly demonstrate increased IL-1
expression in the mammary gland following iFGFR1 activation,
we were interested in identifying the cell types responsible for
IL-1 production following iFGFR1 activation. Although activa-
tion of oncogenes has been shown to induce expression of IL-
1 in tumour cells, we were unable to detect secreted IL-1 in
the media of HC-11/R1 cells following iFGFR1 activation
(data not shown). Furthermore, treatment of HC-11/R1 cells
with an IL-1 blocking antibody at the time of AP20187 stim-
ulation did not affect expression of Cox-2, suggesting that
iFGFR1-induced expression of Cox-2 through an IL-1 inde-
pendent pathway. However, co-culture of HC-11/R1 cells with
either RAW 264.7 cells or bone marrow derived macrophages
with HC-11/R1 cells resulted in a significant increase in IL-1
mRNA and protein secretion. Based on these studies, we pro-
pose that the majority of the IL-1 being produced in vivo is
coming primarily from the macrophages, which are known to
express high levels of IL-1 during inflammatory reactions.
However, it is possible that IL-1 is also secreted by other cell
types in the mammary gland, such as fibroblasts. Further stud-
Figure 6
Effects of celecoxib on iFGFR1-induced mammary tumourigenesis Effects of celecoxib on iFGFR1-induced mammary tumourigenesis. (a to c) H&E-stained sections from non-transgenic control mice and mouse 
mammary tumour virus (MMTV) inducible fibroblast growth factor receptor 1 (iFGFR1) transgenic mice following treatment of mice with AP20187 in 
the presence or absence of celecoxib showing example of representative budding structures observed in each group of mice. Magnification bar = 
50 M. (d) Extent of epithelial budding was quantified in sections from the mice described in panel a. Structures were classified as either containing 
no discernible budding structures (none), one to three lateral buds (moderate), or four or more budding structures (extensive) Error bars represent 
standard error of the mean. ** P < 0.01, *** P < 0.001. NS = not significant.Breast Cancer Research    Vol 11 No 2    Reed et al.
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ies are required to delineate the mechanisms by which IL-1
expression is induced in this model.
It is clear that iFGFR1 activation promotes an increase in IL-1
within the microenvironment, which can then act on the epithe-
lial cells to promote tumourigenesis. Therefore, further studies
were performed to examine the specific effects of exogenous
IL-1 on epithelial cells to mimic the increased levels of IL-1
within the microenvironment. Recent studies have demon-
strated that inflammatory cytokines have profound effects on
mammary epithelial cell function [37]. For example, treatment
of breast cancer cells with IL-1 has been reported to activate
the NFB pathway and induce both cell migration and prolifer-
ation [27,28,35]. However, the effects of IL-1 on normal
mammary epithelial cells have not been described. Therefore,
we initially evaluated the effects of IL-1 on NFB activation,
proliferation and migration. IL-1 alone activated NFB, sug-
gesting that the IL-1R signalling pathway is intact in mammary
epithelial cells. However, treatment of cells with IL-1 did not
promote either migration or proliferation of the HC-11/R1
cells. Interestingly, we found that activation of iFGFR1 in the
presence of exogenous IL-1 resulted in increased migration
compared with iFGFR1 activation alone. In contrast to the lack
of effect of IL-1 on iFGFR1-induced proliferation of the HC-
11/R1 cells, the IL-1 neutralising studies suggested that IL-
1 promotes mammary epithelial cell proliferation in vivo.
Therefore, it is important to consider that inflammatory media-
tors may have different effects on epithelial cells depending on
the context of the microenvironment. In addition, it is possible
that IL-1 affects mammary epithelial cell proliferation indi-
rectly by acting on other cell types in the mammary gland. Fur-
ther studies in which IL-1 signalling is impaired in specific cell
types in the mammary gland would be required to elucidate
these interactions.
Because Cox-2 is a downstream target of IL-1, further stud-
ies focused on the ability of IL-1 to promote expression of
Cox-2 in mammary epithelial cells. Cox-2 is expressed in
human breast tumours and has been found in both early-stage
atypical hyperplasias and invasive cancers [38]. However,
recent studies have suggested that in contrast to previous
studies, Cox-2 expression is decreased in invasive breast can-
cers [34,39,40]. Therefore, although the use of Cox-2 inhibi-
tors in late-stage breast cancer may be limited,
epidemiological studies suggest that Cox-2 inhibition may be
relevant for breast cancer prevention. Interestingly, our results
suggest that induction of Cox-2 expression alone is insufficient
to drive tumourigenic alterations of normal epithelial cells such
as migration and proliferation, because treatment of cells with
IL-1 alone resulted in increased Cox-2 but did not promote
these phenotypes. However, in combination with a single
oncogenic stimulus, iFGFR1 activation, Cox-2 was able to par-
ticipate in the acquisition of cell motility. These data suggest
that the functions of Cox-2 in breast cancer are likely to be
dependent on the stage of cancer and the context of the
microenvironment rather than the levels of protein expression.
Cox-2-selective inhibitors have previously been shown to
inhibit mammary tumour formation in mouse mammary tumour
models [30]. However, due to the stochastic nature of these
tumour models, it is difficult to determine the effects of Cox-2
inhibition during the initiating events in tumourigenesis.
Because there is substantial interest in the ability of anti-
inflammatory drugs to reduce the risk of developing breast
cancer, inducible models of mammary tumourigenesis provide
a unique opportunity to study the contributions of inflammation
to breast tumourigenesis. Our results from the Cox-2 inhibition
in vivo studies demonstrate that inhibition of Cox-2 prior to
activating the initial oncogenic stimulus may be sufficient to
delay the formation of early-stage lesions in the breast. Inter-
estingly, gross comparison of the mammary glands using
whole mounts suggested that Cox-2 inhibition did not appear
to be as effective as IL-1 inhibition. Therefore, comparisons
between different methods of inhibiting IL-1 and Cox-2 in this
model may provide insights into which of these inflammatory
mediators might represent a more effective anti-inflammatory
target. Finally, further studies of this model will provide impor-
tant insights into the role of inflammation in promoting breast
tumour formation, which may be particularly relevant to sub-
sets of patients that have high levels of inflammatory mediators
associated with pre-invasive lesions in the breast.
Conclusions
Studies of growth factor signalling pathways in breast cancer
have produced a wealth of information regarding the effects of
these pathways on tumour formation and progression. How-
ever, it is becoming more apparent that tumours are the result
of a complex interplay bet ween intracellular signalling path-
ways and extracellular stimuli. Although several growth factor
receptors, such as epidermal growth factor receptor, ErbB2
and FGFR1, have been studied and implicated in breast can-
cer, we are only beginning to understand how these growth
factor pathways interact with other autocrine or paracrine fac-
tors to promote tumourigenesis. Although inflammatory
cytokines have been implicated in breast cancer, it is clear that
these cytokines alone are not sufficient to cause tumour forma-
tion. In fact, it is well accepted that cancer does not develop
due to a single genetic alteration, but instead requires the
contribution of multiple factors, both within the cell and in the
microenvironment. Understanding how these various factors
cooperate within epithelial and tumour cells to promote breast
cancer initiation and formation will lead to the development of
more effective combinatorial therapies designed to target mul-
tiple pathways within both the tumour cells and the supporting
stromal cells.
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